Evidence map›Paper›PMID 37212600›Full record

Trial reportCirculation2023

Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.

Stephen J Greene, Eric J Velazquez, Kevin J Anstrom, Robert M Clare, Tracy A DeWald, Mitchell A Psotka, Andrew P Ambrosy, Gerin R Stevens, John J Rommel, Tamas Alexy and 7 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled TrialPragmatic Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03296813 (TRANSFORM-HF), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03296813 phase3completednot on this map

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

TypeinterventionalSponsorDuke UniversityRan2018 to 2022Enrolled2,973ConditionsHeart FailureArmsTorsemide, Furosemide
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 4 countries.

Stephen J GreeneDuke Clinical Research Institute, Durham, NC (S.J.G., R.M.C., E.L.E., R.J.M.).ORCID 0000-0001-6912-7374
Eric J VelazquezDepartment of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (E.J.V.).ORCID 0000-0003-2245-7477
Kevin J AnstromGillings School of Global Public Health, University of North Carolina, Chapel Hill (K.J.A.).
Robert M ClareDuke Clinical Research Institute, Durham, NC (S.J.G., R.M.C., E.L.E., R.J.M.).
Tracy A DeWaldDivision of Cardiology, Duke University School of Medicine, Durham, NC (S.J.G., T.A.D., R.J.M.).
Mitchell A PsotkaInova Heart and Vascular Institute, Falls Church, VA (M.A.P.).
Andrew P AmbrosyDivision of Research, Kaiser Permanente Northern California, Oakland (A.P.A.).ORCID 0000-0002-4563-1071
Gerin R StevensDepartment of Cardiology, Northwell Health, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, NY (G.R.S.).ORCID 0000-0002-8235-5045
John J RommelNovant Health Heart and Vascular Institute, Wilmington, NC (J.J.R.).
Tamas AlexyDivision of Cardiology, University of Minnesota, Minneapolis (T.A.).
Fassil KetemaDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (F.K., D.-Y.K., P.D.-N.).
Dong-Yun KimDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (F.K., D.-Y.K., P.D.-N.).
Patrice Desvigne-NickensDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (F.K., D.-Y.K., P.D.-N.).ORCID 0000-0003-1073-641X
Bertram PittDepartment of Medicine, Division of Cardiology, University of Michigan, Ann Arbor (B.P.).
Eric L EisensteinDuke Clinical Research Institute, Durham, NC (S.J.G., R.M.C., E.L.E., R.J.M.).ORCID 0000-0003-0216-428X
Robert J MentzDuke Clinical Research Institute, Durham, NC (S.J.G., R.M.C., E.L.E., R.J.M.).ORCID 0000-0002-3222-1719
TRANSFORM-HF Investigators
Duke University · USNational Heart Lung and Blood Institute · USClinical Research Institute · USAlaska Heart and Vascular Institute · USKaiser Permanente · USNorthwell Health · USNovant Health · USUniversity of Michigan · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
TRANSFORM-HF CCCU01HL125511 · NHLBI · YALE UNIVERSITY · PI MENTZ, ROBERT JOHN, VELAZQUEZ, ERIC J · 2017 to 2021
$7.7M
TRANSFORM-HF DCCU01HL125478 · NHLBI · DUKE UNIVERSITY · PI CHAKRABORTY, HRISHIKESH · 2017 to 2021
$3.7M
Cardio-Renal Effects of Torsemide vs. Furosemide: A TRANSFORM-HF Mechanistic Sub-StudyR01HL148354 · NHLBI · YALE UNIVERSITY · PI TESTANI, JEFFREY M · 2019 to 2022
$3.3M
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalizationR01HL154768 · NHLBI · INOVA HEALTH CARE SERVICES · PI COOPER, LAUREN BETH, DEFILIPPI, CHRISTOPHER R · 2020 to 2023
$1.6M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL148354NHLBI NIH HHS R01 HL154768NHLBI NIH HHS U01 HL125478NHLBI NIH HHS U01 HL125511
6 · The paper itself

Abstract

backgroundLoop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown. As prespecified secondary end points, the TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) compared the effect of torsemide versus furosemide on patient-reported outcomes among patients with HF.

methodsTRANSFORM-HF was an open-label, pragmatic, randomized trial of 2859 patients hospitalized for HF (regardless of ejection fraction) across 60 hospitals in the United States. Patients were randomly assigned in a 1:1 ratio to a loop diuretic strategy of torsemide or furosemide with investigator-selected dosage. This report examined effects on prespecified secondary end points, which included Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS; assessed as adjusted mean difference in change from baseline; range, 0-100 with 100 indicating best health status; clinically important difference, ≥5 points) and Patient Health Questionnaire-2 (range, 0-6; score ≥3 supporting evaluation for depression) over 12 months.

resultsBaseline data were available for 2787 (97.5%) patients for KCCQ-CSS and 2624 (91.8%) patients for Patient Health Questionnaire-2. Median (interquartile range) baseline KCCQ-CSS was 42 (27-60) in the torsemide group and 40 (24-59) in the furosemide group. At 12 months, there was no significant difference between torsemide and furosemide in change from baseline in KCCQ-CSS (adjusted mean difference, 0.06 [95% CI, -2.26 to 2.37];

conclusionsAmong patients discharged after hospitalization for HF, a strategy of torsemide compared with furosemide did not improve symptoms or quality of life over 12 months. The effects of torsemide and furosemide on patient-reported outcomes were similar regardless of ejection fraction, previous loop diuretic use, and baseline health status. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03296813.

Indexed as

FurosemideHeart FailureHumansQuality of LifeSodium Potassium Chloride Symporter InhibitorsStroke VolumeTorsemideFurosemideSodium Potassium Chloride Symporter InhibitorsTorsemidecardiomyopathiesdiureticsfurosemideheart failurepatient reported outcome measurestorsemide

Identifiers

PMID37212600
PMCPMC10524905
OpenAlexW4377220140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.